Cantor Fitzgerald Reiterates Overweight Rating on PTC Therapeutics (PTCT)

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $113.00 price target on PTC Therapeutics (NASDAQ: PTCT).

The analyst commented, "We are updating our PTCT model for the quarter ending December 31, 2024. There are no changes to our 12-month PT of $113. The company previously reported preliminary revenues for 2024; we changed to the actuals reported. We have made adjustments to our operating expenses and revenues based on 2025E guidance (we updated our numbers to be within the range guided, leading to slightly lower revenues) which results in the changes to our model."

For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.

Shares of PTC Therapeutics closed at $55.26 yesterday.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Axis Capital Limited Downgrades Landmark Cars (LANDMARK:IN) to Add (2)
• JPMorgan Upgrades Astral Ltd (ASTRA:IN) to Overweight